ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
OncoCyte Corporation

OncoCyte Corporation (OCX)

3,72
0,00
(0,00%)
Fermé 21 Décembre 10:00PM
0,00
0,00
(0,00%)
Après les heures de négociation: -

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

Dernier
3,72
Prix Achat
-
Prix Vente
-
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Cap du marché
Clôture Veille
3,72
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
-
Actions en circulation
8 261 000
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-0,64
Bénéfice par action (BPA)
-3,48
Chiffre d'affairess
7,27M
Bénéfice net
-28,72M

À propos de OncoCyte Corporation

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers.... OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests. Show more

Secteur
In Vitro,in Vivo Diagnostics
Industrie
In Vitro,in Vivo Diagnostics
Site Web
Siège social
Irvine, California, USA
Fondé
-

OCX Dernières nouvelles

EchelonDx & Oncocyte Announce Collaboration to Create Seamless Informatics Software to Scale Proprietary Clinical Test Offeri...

Echelon Diagnostics, Inc., a leading provider of genomic healthcare AI imaging and big data solutions, today announced a strategic collaboration with Oncocyte Corporation (NYSE American: OCX), a...

BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias

ALAMEDA, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today provided a business update...

OncoCyte Reports Second Quarter 2018 Financial Results and Positive Corporate Developments

-Encouraging Study Data Drives Continued Development of DetermaVu™ Lung Cancer Diagnostic Test- -Conference Call Today at 4:30 pm ET- ALAMEDA, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE...

Seasoned Healthcare Executive Albert P. Parker Appointed Chief Operating Officer of OncoCyte

ALAMEDA, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today...

OncoCyte to Report Second Quarter 2018 Financial Results on August 14, 2018

ALAMEDA, Calif., July 30, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, announced...

OncoCyte Announces At-Market $3.59 Million Offering of Common Stock and Warrants

ALAMEDA, Calif., July 27, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy diagnostic tests for the early detection of cancer...

OncoCyte Reports Encouraging New Study Results for Lung Cancer Blood Test

- Results suggest improved performance of next-generation test- Study results support move to new diagnostic testing platform- Significant development work required to fully validate this recent...

OncoCyte Reports First Quarter 2018 Financial Results

ALAMEDA, Calif., May 15, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today reported financial...

OncoCyte to Report First Quarter 2018 Financial Results on May 15, 2018

ALAMEDA, Calif, May 08, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, announced...

Leading Molecular Diagnostics Executive Ronnie Andrews Appointed to OncoCyte’s Board of Directors

ALAMEDA, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX) today announced the appointment of Ronald Andrews, Jr., an executive with over 30 years’...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

OCX - Frequently Asked Questions (FAQ)

What is the current OncoCyte share price?
The current share price of OncoCyte is US$ 3,72
How many OncoCyte shares are in issue?
OncoCyte has 8 261 000 shares in issue
What is the market cap of OncoCyte?
The market capitalisation of OncoCyte is USD 30,73M
What is the 1 year trading range for OncoCyte share price?
OncoCyte has traded in the range of US$ 0,00 to US$ 0,00 during the past year
What is the PE ratio of OncoCyte?
The price to earnings ratio of OncoCyte is -0,64
What is the cash to sales ratio of OncoCyte?
The cash to sales ratio of OncoCyte is 2,51
What is the reporting currency for OncoCyte?
OncoCyte reports financial results in USD
What is the latest annual turnover for OncoCyte?
The latest annual turnover of OncoCyte is USD 7,27M
What is the latest annual profit for OncoCyte?
The latest annual profit of OncoCyte is USD -28,72M
What is the registered address of OncoCyte?
The registered address for OncoCyte is 15 CUSHING, IRVINE, CALIFORNIA, 92618
What is the OncoCyte website address?
The website address for OncoCyte is www.oncocyte.com
Which industry sector does OncoCyte operate in?
OncoCyte operates in the IN VITRO,IN VIVO DIAGNOSTICS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
MGLDMarygold Companies Inc
US$ 2,053
(48,77%)
128,45k
MINFT Limited
US$ 7,25
(44,22%)
948,89k
CTMCastellum Inc
US$ 0,578
(41,01%)
8,94M
KULRKULR Technology Group Inc
US$ 2,885
(28,79%)
75,72M
MSTUT Rex 2X Long MSTR Daily Target ETF
US$ 12,49
(22,81%)
64,96M
BATLBattalion Oil Corporation
US$ 1,3499
(-44,56%)
1,63M
NVOXDefiance Daily Target 2x Long Nvo ETF
US$ 11,5991
(-35,47%)
407,1k
UVIX2x Long VIX Futures ETF
US$ 3,83
(-29,07%)
70,61M
TPETTrio Petroleum Corp
US$ 1,10
(-25,17%)
2,81M
MSTZT Rex 2X Inverse MSTR Daily Target ETF
US$ 19,235
(-23,06%)
21,33M
SPYSPDR S&P 500
US$ 591,15
(0,86%)
122,49M
SPXSDirexion Daily S&P 500 Bear 3X Shares New
US$ 6,1628
(-3,25%)
114,87M
SOXLDirexion Daily Semiconductor Bull 3X Shares
US$ 27,30
(3,80%)
108,08M
TSLZT Rex 2X Inverse Tesla Daily Target ETF
US$ 2,435
(7,27%)
94,23M
KULRKULR Technology Group Inc
US$ 2,885
(28,79%)
75,72M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock